Past 10 year's financial track record analysis by Moneyworks4me indicates that Rossari Biotech Ltd is a good quality company.
The key valuation ratios of Rossari Biotech Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Rossari Biotech Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 10.7% | 10.3% | 26.4% | 40.4% | 54.4% | 37.9% | 28.8% | 24.4% | 18.5% | 18.4% | - |
| Value Creation Index ⓘ | -0.2 | -0.3 | 0.9 | 1.9 | 2.9 | 1.7 | 1.1 | 0.8 | 0.3 | 0.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 171 | 179 | 233 | 292 | 516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 1,924 |
| Sales YoY Gr. | - | 4.4% | 30.6% | 25% | 76.9% | 16.3% | 18.2% | 109.1% | 11.7% | 10.6% | - |
| Adj EPS ⓘ | 0.8 | 0.7 | 3.3 | 5.9 | 9.5 | 12.6 | 15.3 | 16.3 | 18.3 | 22.6 | 25.1 |
| YoY Gr. | - | -7.9% | 364.3% | 81.9% | 60.1% | 33.1% | 21.8% | 6% | 12.9% | 23.1% | - |
| BVPS (₹) ⓘ | 9.7 | 10.3 | 13.5 | 19.5 | 25.6 | 56.4 | 78.3 | 145.7 | 165.3 | 189 | 201.9 |
| Adj Net Profit ⓘ | 3.7 | 3.4 | 15.7 | 28.6 | 45.8 | 63.9 | 79.6 | 89.5 | 101 | 125 | 139 |
| Cash Flow from Ops. ⓘ | 8.1 | 25.7 | 7.2 | 23.6 | 71.2 | 56.8 | 47.8 | 29.4 | 152 | 43.3 | - |
| Debt/CF from Ops. ⓘ | 5.4 | 0.9 | 3.1 | 0.9 | 0.1 | 1.2 | 0 | 0.3 | 0.5 | 2.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 30.1% | 28.8% | 37.2% | 10.6% | ||||
| Adj EPS ⓘ | 45.8% | 19% | 13.8% | 23.1% | ||||
| BVPSⓘ | 39.1% | 49.2% | 34.1% | 14.4% | ||||
| Share Price | - | - | -14.5% | 0.6% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 7.7 | 7 | 27.3 | 35.8 | 42 | 31.1 | 22.9 | 14.7 | 11.8 | 12.7 | 12.8 |
| Op. Profit Mgn % ⓘ | 8.6 | 7 | 10.4 | 15.3 | 15.1 | 17.5 | 17.4 | 11.9 | 13 | 13.3 | 13.4 |
| Net Profit Mgn % ⓘ | 2.2 | 1.9 | 6.7 | 9.8 | 8.9 | 10.7 | 11.2 | 6 | 6.1 | 6.8 | 7.2 |
| Debt to Equity ⓘ | 0.9 | 0.5 | 0.3 | 0.2 | 0 | 0.2 | 0 | 0 | 0.1 | 0.1 | 0.1 |
| Working Cap Days ⓘ | 153 | 132 | 107 | 109 | 107 | 140 | 163 | 134 | 166 | 189 | 82 |
| Cash Conv. Cycle ⓘ | 81 | 62 | 42 | 45 | 24 | 13 | 29 | 46 | 68 | 79 | 42 |
Sales growth is growing at healthy rate in last 3 years 37.16%
Net Profit is growing at healthy rate in last 3 years 13.76%
Sales growth is good in last 4 quarters at 14.44%
Return on Equity has declined versus last 3 years average to 12.80%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 18.7 | 25.1 |
| TTM Sales (₹ Cr.) | 1,249 | 1,924 |
| BVPS (₹.) ⓘ | 182.8 | 201.9 |
| Reserves (₹ Cr.) ⓘ | 999 | 1,107 |
| P/BV ⓘ | 4.45 | 4.02 |
| PE ⓘ | 43.48 | 32.42 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 657.80 / 966.00 |
| All Time Low / High (₹) | 536.10 / 1620.60 |
| Market Cap (₹ Cr.) | 4,498 |
| Equity (₹ Cr.) | 11.1 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 58.6 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 171 | 179 | 233 | 292 | 516 | 600 | 709 | 1,483 | 1,656 | 1,831 |
| Operating Expenses ⓘ | 156 | 166 | 209 | 247 | 439 | 495 | 586 | 1,307 | 1,441 | 1,587 |
| Manufacturing Costs | 4 | 4 | 6 | 3 | 13 | 14 | 21 | 38 | 49 | 64 |
| Material Costs | 123 | 131 | 166 | 197 | 339 | 372 | 462 | 1,108 | 1,171 | 1,294 |
| Employee Cost | 11 | 12 | 14 | 20 | 28 | 37 | 42 | 68 | 99 | 103 |
| Other Costs ⓘ | 18 | 20 | 23 | 28 | 59 | 73 | 61 | 93 | 123 | 127 |
| Operating Profit ⓘ | 15 | 13 | 24 | 45 | 78 | 105 | 123 | 176 | 215 | 243 |
| Operating Profit Margin (%) | 8.5% | 7.0% | 10.4% | 15.3% | 15.0% | 17.5% | 17.3% | 11.9% | 13.0% | 13.3% |
| Other Income ⓘ | 0 | 0 | 1 | 1 | 1 | 4 | 9 | 19 | 14 | 14 |
| Interest ⓘ | 5 | 4 | 2 | 1 | 3 | 4 | 3 | 13 | 22 | 19 |
| Depreciation ⓘ | 5 | 5 | 4 | 5 | 12 | 17 | 23 | 48 | 63 | 60 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 5 | 5 | 19 | 40 | 63 | 88 | 107 | 136 | 144 | 178 |
| Tax ⓘ | 1 | 1 | 3 | 11 | 18 | 23 | 27 | 39 | 37 | 47 |
| Profit After Tax | 4 | 3 | 16 | 29 | 46 | 65 | 80 | 98 | 107 | 131 |
| PAT Margin (%) | 2.2% | 1.9% | 6.7% | 9.9% | 8.8% | 10.9% | 11.3% | 6.6% | 6.5% | 7.1% |
| Adjusted EPS (₹) | 0.8 | 0.7 | 3.3 | 6.0 | 9.4 | 12.9 | 15.5 | 17.7 | 19.5 | 23.7 |
| Dividend Payout Ratio (%) | 6% | 0% | 0% | 30% | 5% | 4% | 3% | 3% | 3% | 2% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 47 | 50 | 65 | 94 | 124 | 286 | 407 | 802 | 912 | 1,044 |
| Share Capital ⓘ | 4 | 4 | 4 | 4 | 4 | 10 | 10 | 11 | 11 | 11 |
| Reserves ⓘ | 42 | 46 | 61 | 90 | 119 | 276 | 396 | 791 | 901 | 1,033 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 39 | 22 | 22 | 20 | 4 | 61 | 0 | 0 | 64 | 96 |
| Long Term Debt | 9 | 7 | 2 | 1 | 1 | 34 | 0 | 0 | 35 | 33 |
| Short Term Debt | 30 | 15 | 20 | 19 | 3 | 27 | 0 | 0 | 29 | 63 |
| Trade Payables | 18 | 28 | 32 | 40 | 106 | 97 | 131 | 186 | 181 | 219 |
| Others Liabilities ⓘ | 10 | 8 | 5 | 11 | 49 | 80 | 107 | 429 | 415 | 465 |
| Total Liabilities ⓘ | 114 | 109 | 124 | 166 | 283 | 525 | 645 | 1,417 | 1,572 | 1,825 |
Fixed Assets | ||||||||||
| Gross Block | 67 | 38 | 76 | 88 | 86 | 122 | 234 | 704 | 743 | 791 |
| Accumulated Depreciation | 30 | 0 | 38 | 43 | 12 | 29 | 53 | 97 | 158 | 213 |
| Net Fixed Assetsⓘ | 38 | 38 | 38 | 45 | 74 | 94 | 181 | 607 | 585 | 578 |
| CWIP ⓘ | 7 | 8 | 8 | 10 | 3 | 22 | 0 | 1 | 16 | 47 |
| Investmentsⓘ | 0 | 0 | 0 | 7 | 0 | 18 | 0 | 36 | 51 | 63 |
| Inventories | 31 | 25 | 24 | 35 | 55 | 58 | 95 | 190 | 188 | 282 |
| Trade Receivables | 30 | 31 | 47 | 60 | 86 | 94 | 144 | 305 | 354 | 425 |
| Cash Equivalents | 1 | 3 | 2 | 1 | 6 | 127 | 88 | 52 | 124 | 30 |
| Others Assetsⓘ | 7 | 5 | 5 | 8 | 59 | 112 | 135 | 225 | 253 | 399 |
| Total Assets ⓘ | 114 | 109 | 124 | 166 | 283 | 525 | 645 | 1,417 | 1,572 | 1,825 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 8 | 26 | 7 | 24 | 71 | 57 | 48 | 29 | 152 | 43 |
| PBT ⓘ | 5 | 5 | 19 | 40 | 63 | 88 | 107 | 136 | 144 | 178 |
| Adjustment ⓘ | 9 | 7 | 6 | 6 | 17 | 20 | 21 | 55 | 83 | 76 |
| Changes in Working Capital ⓘ | -5 | 13 | -14 | -11 | 11 | -31 | -48 | -112 | -28 | -157 |
| Tax Paid ⓘ | -1 | -1 | -3 | -11 | -20 | -20 | -31 | -50 | -48 | -54 |
| Cash Flow From Investing Activity ⓘ | -2 | -5 | -6 | -20 | -36 | -190 | -37 | -299 | -181 | -103 |
| Capex | -2 | -5 | -6 | -14 | -44 | -76 | -56 | -36 | -31 | -126 |
| Net Investments | 0 | 0 | 0 | 0 | 7 | -18 | 14 | -6 | -14 | -9 |
| Others ⓘ | 0 | 0 | 0 | -7 | 1 | -96 | 5 | -257 | -136 | 32 |
| Cash Flow From Financing Activityⓘ | -6 | -19 | -2 | -5 | -29 | 157 | -25 | 292 | 61 | 16 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 100 | 43 | 302 | 4 | 4 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | -1 | 39 | -34 | 0 | 45 | -12 |
| Interest Paid ⓘ | -5 | -3 | -2 | -1 | -2 | -3 | -4 | -2 | -6 | -16 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | -11 | -3 | -3 | -3 | -3 | -3 |
| Others ⓘ | -2 | -17 | 0 | -4 | -16 | 24 | -27 | -5 | 21 | 43 |
| Net Cash Flow ⓘ | 0 | 2 | 0 | -2 | 6 | 23 | -14 | 22 | 32 | -44 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 8.18 | 6.99 | 27.27 | 36.33 | 41.88 | 31.83 | 23.11 | 16.17 | 12.52 | 13.36 |
| ROCE (%) | 10.7 | 10.3 | 26.4 | 40.37 | 54.4 | 37.93 | 28.81 | 24.37 | 18.48 | 18.39 |
| Asset Turnover Ratio | 1.43 | 1.6 | 2 | 2.06 | 2.3 | 1.49 | 1.22 | 1.45 | 1.11 | 1.08 |
| PAT to CFO Conversion(x) | 2 | 8.67 | 0.44 | 0.83 | 1.54 | 0.88 | 0.6 | 0.3 | 1.42 | 0.33 | Working Capital Days |
| Receivable Days | 62 | 62 | 61 | 66 | 51 | 54 | 61 | 55 | 72 | 77 |
| Inventory Days | 78 | 58 | 38 | 36 | 32 | 34 | 39 | 35 | 42 | 47 |
| Payable Days | 68 | 65 | 66 | 67 | 79 | 100 | 90 | 52 | 57 | 56 |
The company was initially incorporated as Rossari Labtech on March 6, 2003, as a partnership firm under the Indian Partnership Act, 1932, pursuant to a certificate of registration dated June 22, 2003, issued by the Registrar of Firms, Mumbai. The name of the partnership firm was changed to Rossari Biotech on December 5, 2003 and further the firm converted into a joint stock company on August 10, 2009, under part IX of the Companies Act, 1956 as Rossari Biotech Limited with a certificate of incorporation granted by the Registrar of Companies, Maharashtra at Mumbai (RoC). The company received its certificate of commencement of business on August 13, 2009.
Business area of the company
The company is one of the leading specialty chemicals manufacturing companies in India providing customized solutions to specific industrial and production requirements of its customers primarily in the FMCG, apparel, poultry and animal feed industries through its diversified product portfolio comprising home, personal care and performance chemicals; textile specialty chemicals; and animal health and nutrition products. The company’s business is organized in three main product categories - (i) home, personal care and performance chemicals; (ii) textile specialty chemicals; and (iii) animal health and nutrition products.
The company is the leading manufacturer of acrylic polymers in India and manufactures many products for its customers in the soaps and detergent, paints, inks and coatings, ceramics and tiles, water treatment chemicals and pulp and paper industries. It also manufacture institutional cleaning chemical formulations for hospitality, facility management, airports, corporates, food service, commercial laundry, malls, multiplexes, educational sector, places of worship etc. It is in advanced stages of expanding its home, personal care and performance product portfolio to water treatment formulations, specialty formulation for breweries as well as dairies. Besides, the company provides specialty chemicals for the entire value-chain of the textile industry starting from fiber, yarn to fabric, wet processing and garment processing. The company has also diversified into animal health and nutrition and currently supply poultry feed supplements and additives, pet grooming and pet treats including for weaning, infants and adult pets.
Major Events & Milestones:
Awards & accreditations:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
